TP53 and Alzheimer disease: Studies have shown that the CXCL12‐stimulated CXCR4 pathway regulates the activation of AKT, cAMP‐response element‐binding phosphorylation, and P53 levels and affects the process of aging and AD, suggesting that CXCR4 might be a new target and biomarker for the treatment of AD, but the specific mechanism remains to be further investigated42, 47 (CXCL12/CXCR4 participating signaling pathways are shown in Figure 2).